戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  intra-cranial tumors (p = .0074 compared to untreated group).
2 ients to trigger acute rejection (allogeneic untreated group).
3  PNU-120596 (treated group) or vehicle only (untreated group).
4 herapy (DAA group) and 70% were not treated (untreated group).
5 atients with RA or RAEB (160.2% +/- 90.5% of untreated group).
6 ibition) relative to vessels in the control, untreated group.
7 ally labeled 131I-RS11 group and none in the untreated group.
8 ed group and 128 cases were diagnosed in the untreated group.
9  than in isolates obtained from those in the untreated group.
10 ted group compared to minimal changes in the untreated group.
11 lowered the inflammatory markers compared to untreated group.
12  fucoxanthin-treated PL-MSCs compared to the untreated group.
13 eduction of IL-5 was observed in the SLIT or untreated group.
14 le progression pathways in the 4-NQO vs. the untreated group.
15 rom the lungs in both groups and asci in the untreated group.
16 effects in all the assessments compared with untreated group.
17 ctively, compared with 45.5 d in the control untreated group.
18 ify gut tracer retention with respect to the untreated group.
19 eated-XO groups, and 3.2% in the ranibizumab untreated group.
20 he IVB group and 16 eyes of 8 infants in the untreated group.
21 nd visual fields (P = 0.005), compared to an untreated group.
22 ased significantly compared to those for the untreated group.
23 3 +/- 0.011%, p < 0.0001) was lower than the untreated group.
24 7 tumor cells (P < 0.01) as compared with an untreated group.
25 istically significant when compared with the untreated group.
26 mals was significantly less than that in the untreated group.
27 he DZ-treated injury group compared with the untreated group.
28 isease-treated group compared to the disease-untreated group.
29 P<0.0001), with no significant change in the untreated group.
30 gnificantly lower compared with those in the untreated group.
31 nhibitor of NOS-2, and compared them with an untreated group.
32  similar during repeated measurements in the untreated group.
33  significant differences between treated and untreated groups.
34 months from baseline between the treated and untreated groups.
35 was not different between the SB-treated and untreated groups.
36 retinal blood flow, in both the resolved and untreated groups.
37 between the cell therapy and contemporaneous untreated groups.
38 ified differences between EBOTAb-treated and untreated groups.
39  analysis was performed to match treated and untreated groups.
40 es were compared between the treated and the untreated groups.
41 n the composite score between the treated vs untreated groups.
42 t rates between infants from the treated and untreated groups.
43 ooled ranibizumab treated-XO and ranibizumab untreated groups.
44 ed to balance covariates between treated and untreated groups.
45 the caudal cord, a phenomenon not present in untreated groups.
46 pth (P = 0.033) compared to root planing and untreated groups.
47 njury was equally severe in both treated and untreated groups.
48 to treated (partial spectacle correction) or untreated groups.
49 ly reduced villus height in both U74389F and untreated groups.
50  confidence interval [CI]: 9.65, 11.68), and untreated group (10.33 deaths per 100 PY, 95% CI: 9.96,
51 val over an 18-week period compared with the untreated group (100% versus 50%).
52 in the presence of TRAIL (63.0% +/- 10.4% of untreated group [100%]), numbers increased in patients w
53 to-media ratio with CFVs: 0.89+/-0.14 in the untreated group 2 versus 0.11+/-0.04 in the control grou
54 d Kd was higher (lower affinity) than in the untreated group (6.5+/-1.4, p<0.05).
55 ct AEs were less frequent in the ranibizumab untreated group: 6.3% versus 12.5% and 12.1% in the rani
56 d) patients (1 [4%] of 28 patients) than the untreated group (8 [22%] of 37 patients) in this populat
57 he CT-1-treated group was higher than in the untreated group and prevented IRI-induced reduction in t
58 9% was achieved for 36.2% of predictions for untreated groups and 6.2% for treated groups.
59 , TNF-a, G-CSF, and IL-1B levels compared to untreated groups and amplified levels of CD 34 and Sca 1
60 ended survival time (> 2.5 times that of the untreated group) and histologic signs of radiation-induc
61  antiretroviral therapy (ART) (the infected, untreated group), and 15 HIV-positive participants who w
62 ally higher in the treated compared with the untreated group, and this trend was sustained throughout
63 isease (clinical index of 1.6 +/- 0.5 in the untreated group as compared with 0.0 +/- 0.0 for the tre
64 isease (clinical index of 4.3 +/- 0.7 in the untreated group as compared with 0.5 +/- 0.3 for the tre
65 sion improvement or better compared with the untreated group at 12 months regardless of treatment typ
66 I, 20-205 cells/ microL]), compared with the untreated group at 24 weeks.
67 ues for the acute treatment group versus the untreated group at 72 weeks without therapy were as foll
68 n the following groups of rats: (a) control, untreated group, (b) MK-801-treated groups (0.03 to 1.0
69                                           In untreated groups, bcl-2 mRNA decreased significantly ove
70 ower HIV RNA levels at 24 weeks than did the untreated group, but differences were no longer apparent
71 s estimated by comparing between treated and untreated groups by using Cox proportional hazards model
72 and factor XII were decreased in the disease-untreated group compared to the C11C1 disease-treated gr
73 ortion of persons who died was higher in the untreated group compared with either treatment group (Pr
74 indings showed increased liver damage in the untreated group compared with PY.
75 spite these baseline imbalances, treated and untreated groups did not differ in progression to Oxford
76                              The treated and untreated groups did not differ in time to an OHS score
77 groups were compared with those noted in the untreated group during the same periods of observation a
78 hylaxis (prophylaxis group) or no treatment (untreated group) for 24 months.
79 e and after HVPG measurements in the placebo/untreated groups from 20 RCTs.
80   In the ISAACC cohort, the low-PWAD and OSA untreated group had a higher cardiovascular event recurr
81 adjusted Cox proportional hazards model, the untreated group had almost 6-times higher hazard of deat
82 he phentermine/fenfluramine group, while the untreated group had no anorexigen use during the previou
83 were seen in the E2F-decoy group than in the untreated group (hazard ratio 0.34 [95% CI 0.12-0.99]).
84  group and in 52 participants (35.6%) in the untreated group (hazard ratio, 0.55; 95% confidence inte
85                         Rats with NAFLD were untreated (group II, MSG-obesity group) and treated with
86                         Visual acuity in the untreated group improved significantly from 0.44 +/- 0.5
87                         Visual acuity in the untreated group improved significantly from 0.44 0.50 lo
88  was found in the IO group compared with the untreated group in the total cohort (adjusted odds ratio
89 ease in macrolide resistance determinants in untreated groups in an azithromycin mass drug administra
90 ute rejection was similar in the treated and untreated groups in both the prophylaxis (12% vs. 21%; P
91 th normal IOP, eyes with elevated IOP in the untreated group lost 36% of their retinal ganglion cells
92 ated slower MF progression compared with the untreated group (mean [SD] increase of 3.1% [7.4%] vs 10
93  not receive these prescriptions were in the untreated group (n = 1011).
94                                       In the untreated group (n = 112), 59% of patients with a PgR-po
95 nd exposures, respectively) compared with an untreated group (n = 8).
96                                       In the untreated group (n = 9), baseline cortical blood flow (3
97                                              Untreated groups (n = 8 to 9 per group) were compared (a
98                                           An untreated group of 10 rats manifesting chronic rejection
99                           The outcome in our untreated group of patients did not differ from the trea
100                              All treated and untreated groups of amoebae from the 2 strains exhibited
101 sets were randomly assigned to 'treated' or 'untreated' groups of increasing size and voxel-wise incr
102 nequally distributed between the treated and untreated groups or increased mortality by at least 50%.
103 ars compared with 12.4 +/- 4.1 years for the untreated group (P < 0.001).
104 5 years compared with 12.4 4.1 years for the untreated group (P < 0.001).
105 e and 63 +/- 20 mL/min at 120 minutes in the untreated group (p = 0.0001).
106 R, 3.34; 95% CI, 2.09-5.35), and 4.1% in the untreated group (P<.001).
107 tgrowth versus 5 of 12 (42%) patients in the untreated group (P=0.05).
108 ted higher staining of OPN and BSP than both untreated groups (P < 0.05).
109                            Compared with the untreated group, psychotherapy use was not associated wi
110 bitor PJ34 (PJ34) over a 24-hour period; the untreated group received Lactated Ringer (LR) at the sam
111 rences were found between statin-treated and untreated groups regarding rescue therapy intensity or 1
112 ial, ranibizumab treated-XO, and ranibizumab untreated groups, respectively.
113                            In OVT, UDCA, and untreated groups, respectively: Gamma-glutamyltransferas
114                                          The untreated group showed 49% v 57% 10-year recurrence-free
115                                       In the untreated group, staining for ER and PR colocalized with
116 the microneedle treated group as compared to untreated group, suggesting that microneedles promoted i
117 .005; 35% in aged, P <.05) compared with the untreated groups that amounted to more than 1 billion ad
118                                       In the untreated group, the basophil response remained comparab
119 ny Bacillus supplemented groups, compared to untreated group, the group administered with the two L.
120                   Unlike the patients in the untreated group, the patients in the treated group mount
121 d zirconia discs were identified compared to untreated groups (titanium P > 0.05, zirconia P > 0.05).
122                              Compared to the untreated group, treatment with adenosine (7.2 mg/kg) in
123                            Compared with the untreated group, tumors following BRAFi, aPDL1, and CSF1
124 measurements (85.40 +/- 12.18 mul/min in the untreated group versus 142.80 +/- 11.65 mul/min in the e
125 death in the treated group compared with the untreated group was 4.8% (14 out of 292) vs 10.2% (75 ou
126 ination, the mean survival time (MST) of the untreated group was 5.2 +/- 0.8 days.
127 period for children aged 1 to 9 years in the untreated group was 8.3 per 1000 person-years (95% confi
128   Complete protection and superiority to the untreated group was observed among animals whose LEN pla
129 ginterferon alfa-2a group and 6 (19%) in the untreated group were withdrawn prematurely.
130 ginterferon alfa-2a group and 9 (32%) in the untreated group were withdrawn prematurely; whereas in t
131          45 (54%) of the deaths, even in the untreated group, were associated with immaturity.
132     T-kininogen was increased in the disease-untreated group when compared with the C11C1 disease-tre
133 tuzumab and in 20 patients from a previously untreated group who received similar doses subcutaneousl
134 imals treated with soluble receptors and the untreated group with respect to recruitment of inflammat
135 erson-years [95% CI, 0.10 to 0.91]) than the untreated groups with mild to moderate OSA (0.94 per 100
136 losartan-treated (100 mg/L drinking H2O) and untreated groups, with lean Zucker rats as controls.
137                    Rejection occurred in the untreated group within 7 days.

 
Page Top